Evidence map›Paper›PMID 29370196›Full record

ArticlePloS one2018

Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults.

Mary F Kearney, Jonathan Spindler, Ann Wiegand, Wei Shao, Richard Haubrich, Sharon Riddler, Christina M Lalama, Michael D Hughes, John M Coffin, John W Mellors

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Mary F KearneyHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD, United States of America.ORCID 0000-0003-3839-6576
Jonathan SpindlerHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD, United States of America.
Ann WiegandHIV Dynamics and Replication Program, National Cancer Institute, Frederick, MD, United States of America.
Wei ShaoAdvanced Biomedical Computing Center, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, United States of America.
Richard HaubrichDivision of Infectious Diseases, University of California, San Diego, CA (Currently Gilead Sciences, Foster City, CA), United States of America.
Sharon RiddlerDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, United States of America.
Christina M LalamaCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Michael D HughesCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
John M CoffinDepartment of Molecular Biology and Microbiology, Tufts University, Boston, MA, United States of America.
John W MellorsDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA, United States of America.
National Cancer Institute · USCancer Research And Biostatistics · USUniversity of Pittsburgh · USLeidos (United States) · USTufts University · USUniversity of California San Diego · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
Ultrasensitive Single-Genome Sequencing to Study HIV Transmission and EvolutionZIABC011699 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KEARNEY, MARY · 2016 to 2024
$7.1M
Retrovirus Evolution and CancerR35CA200421 · NCI · TUFTS UNIVERSITY BOSTON · PI COFFIN, JOHN M · 2016 to 2022
$6.5M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS R35 CA200421NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI106701NIH HHS UM1AI106701
6 · The paper itself

Abstract

backgroundIdentifying pre-ART factors associated with the emergence of HIV-1 drug resistance is critical for optimizing strategies to prevent virologic failure. A previous study reported that lower pre-ART HIV-1 pol diversity was associated with higher risk of virologic failure in HIV-1-infected children. To investigate this association in adults, we measured HIV-1 diversity with deep sequencing in pre-ART samples from adults with well-characterized virologic outcomes in a study (A5142) of initial ART conducted by the AIDS Clinical Trials Group (ACTG).

methodsWe identified 22 cases in ACTG A5142 who experienced virologic failure with drug resistance mutations in RT and 44 matched controls who did not experience virologic failure. cDNA was synthesized from plasma HIV-1 RNA. Each cDNA molecule was tagged with a unique primer ID and RT codons 41-103 were amplified and deep sequenced. Sequences with the same tag were aligned and a consensus was generated to reduce PCR and sequencing errors. Diversity was calculated by measuring average pairwise distance (APD) of the consensus sequences. An exact conditional logistic regression model with percent APD as the risk factor estimated the odds ratio for VF and the corresponding 95% confidence interval.

resultsConsensus single-genome sequences and diversity estimates of pol were obtained for pre-ART samples from 21 cases and 42 controls. The median (IQR) pre-ART percent APD was 0.71 (0.31-1.13) in cases and 0.58 (0.32-0.94) in controls. A possible trend was found for higher diversity being associated with greater risk of virologic failure in adults (OR = 2.2 per one percent APD increase, 95% CI = [0.8, 7.2]; p = 0.15).

conclusionsThis study in adults suggests there is a positive association between higher pre-ART pol diversity and the risk of virologic failure in adults rather than an inverse relationship reported in children.

Indexed as

Genes, polGenetic VariationCase-Control StudiesCD4 Lymphocyte CountDrug Resistance, ViralHIV-1HIV InfectionsHumansPolymerase Chain ReactionViral Load

Identifiers

PMID29370196
PMCPMC5784902
OpenAlexW2790206307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.